20 results about "Immunologic specificity" patented technology

Myocilin-binding agents including antibodies and antigen binding fragments thereof and fusion proteins that immunospecifically bind the coiled-coil domain of myocilin but do not bind to misfolded myocilin are provided herein. The disclosed antibodies and antigen binding fragments and fusion proteins are useful for the detection and extraction of natively folded myocilin from a sample.

Myocilin-binding agents including antibodies and antigen binding fragments thereof and fusion proteins that immunospecifically bind the coiled-coil domain of myocilin but do not bind to misfolded myocilin are provided herein. The disclosed antibodies and antigen binding fragments and fusion proteins are useful for the detection and extraction of natively folded myocilin from a sample.

Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to BTN1A1. Methods of making and using these molecules are also provided, including methods of using them in detecting the presence of BTN1A1 in a sample, such as a bodily fluid or tissue of a patient, for diagnostics and treatment of BTN1A1 mediated diseases or conditions.

Provided herein are methods for using antibodies that immunospecifically bind to KIT, a receptor tyrosine kinase, in particular barzolvolimab, to treat, manage or prevent urticaria. Also provided are kits and pharmaceutical dosage units of antibodies that immunospecifically bind to KIT, in particular barzolvolimab.

Provided herein are pharmaceutical compositions comprising antibodies that immunospecifically bind to KIT, a receptor tyrosine kinase, and uses thereof. Also provided are kits and methods for producing such pharmaceutical compositions. KIT (or c-Kit) is a type III receptor tyrosine kinase encoded by the c-kit gene. KIT comprises five extracellular immunoglobulin (ig)-like domains, a single transmembrane region, an inhibitory cytoplasmic juxtamembrane domain, and a split cytoplasmic kinase domain separated by a kinase insert segment.

The present invention relates to a method of detecting liver cancer in a mammalian subject by detecting an antibody in a test sample comprising a bodily fluid from the mammalian subject, wherein the antibody is an autoantibody immunologically specific for a tumour marker protein selected from the group consisting of MMP9, AIF1, EpCAM and CDKN1B, which method comprises contacting the test sample with a tumour marker antigen selected from the group consisting of MMP9, AIF1, EpCAM and CDKN1B and determining the presence or absence of complexes of the tumour marker antigen bound to autoantibodies present in the test sample where the presence of said complexes is indicative of the presence of liver cancer. Also included within the invention are corresponding methods of diagnosing and treating liver cancer in a mammalian subject, corresponding methods of predicting response to an anti-liver cancer treatment, a corresponding method of detecting an antibody in a test sample comprising a bodily fluid from a mammalian subject and kits suitable for performing methods of the invention.

Disclosed herein are fully human antibody molecules that immunospecifically bind to human IL-5. The antibody molecules can bind to human IL-5 with an equilibrium affinity constant (KD) of at least about 40 pM as determined by surface plasmon resonance.

Compositions and methods of their use to detect and treat anti-PD1 therapy resistance are provided herein. Compositions that immunospecifically bind and deplete dysfunctional T cells are provided. The dysfunctional T cells that are depleted include CD38+PD-1+ T cells, CD38+CD8+ T-cells, or both. The dysfunctional T cells can be depleted, for example, by administering an antibody or fusion protein that specifically binds to dysfunctional T cells and promotes their depletion. In one embodiment the antibody is a bispecific antibody that can be specific for CD38 and CD8, or it can be specific for CD38 and PD-1. Also disclosed is a method of detecting and treating anti-PD1 therapy resistance by measuring the amount of CD38+PD1+CD8 T cells in blood or tissue samples obtained from a subject prior to anti-PD1 therapy and administering an anti-CD38 / CD8 or anti-CD38 / PD-1 depleting / blocking antibody to the subject prior to anti-PD1 therapy.

Provided herein are methods of treating cancer using molecules having an antigen-binding fragment that immunospecifically binds to BTN1A1, e.g., anti-BTN1A1 antibodies. These molecules include those having an antigen-binding fragment that immunospecifically binds to glycosylated BTN1A1, e.g., anti-glycosylated BTN1A1 antibodies. Also included are molecules having an antigen-binding fragment that immunospecifically binds to BTN1A1 dimers, e.g., anti-BTN1A1 dimer antibodies. Also provided are methods of treating cancers resistant or refractory to anti-PD-1 or anti-PD-L1 therapy. [Selected Figure] Figure 1

Described are viral vectors, compositions, kits, and methods or using the vectors, compositions, kits to modulate immune response in a subject. The viral vectors include therapeutic recombinant adeno-associated viruses (rAAVs) and tolerance inducing gene therapy vectors. The therapeutic rAAVs and tolerance inducing gene therapy vectors can be used to deliver one or more therapeutic nucleic acids to the subject. The tolerance inducing gene therapy vectors induce immune-specific tolerance to the therapeutic rAAVs to improve efficacy of the therapeutic rAAVs and allow for multiple administrations of the therapeutic rAAVs with little or no associated immune response to the therapeutic rAAVs. The therapeutic rAAVs can be used to administer a therapeutic effect to the subject.

The present invention provides methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands. The present invention provides methods of treating cancer using a molecule having an antigen binding fragment that immunospecifically binds to BTN1A1 or a BTN1A1 ligand, such as an anti-BTN1A1 antibody or an anti-BTN1A1 ligand antibody. The present invention also provides a BTN1A1 ligand, such as a galectin-1 (galectin-1), a galectin-9 (galectin-9), a neuropilin-2 (Neuropilin-2), and a B-and T-lymphocyte attenuating protein, for example, a BTN1A1 ligand, for example, a Galectin-1 (Galectin-1), a Galectin-9 (Galectin-9), a Galectin-9 (Galectin-9), a Galectin-2 (

To provide a molecule having an antigen binding fragment that immunospecifically binds to BTN1A1, which is useful in cancer treatment or as a cancer diagnosis.SOLUTION: There is provided a molecule having an antigen binding fragment that immunospecifically binds to BTN1A1, for example, an antigen binding fragment that binds to glycosylated BTN1A1 with a Kd less than half of the Kd exhibited relative to unglycosylated BTN1A1, wherein optionally, the antigen binding fragment binds to glycosylated BTN1A1 with a Kd at least 10 times less than the Kd exhibited relative to unglycosylated BTN1A1, for example, an anti-glycosylated BTN1A1 antibody is provided.SELECTED DRAWING: None

The present invention provides methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands. The present invention provides methods of treating cancer using a molecule having an antigen binding fragment that immunospecifically binds to BTN1A1 or a BTN1A1 ligand, such as an anti-BTN1A1 antibody or an anti-BTN1A1 ligand antibody. The present invention also provides a BTN1A1 ligand, such as a galectin-1 (galectin-1), a galectin-9 (galectin-9), a neuropilin-2 (Neuropilin-2), and a B-and T-lymphocyte attenuating protein, for example, a BTN1A1 ligand, for example, a Galectin-1 (Galectin-1), a Galectin-9 (Galectin-9), a Galectin-9 (Galectin-9), a Galectin-2 (

Provided herein are combination treatments comprising molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies, and chemotherapeutic agents for treating cancer. These molecules include those having an antigen binding fragment that immunospecifically binds to BTN1A1. These methods of treatment include eliminating the cancer cells and / or sensitizing the cancer cells for treatment with the chemotherapeutic agent.

Provided herein are molecules or antibodies that immunospecifically binds to a surface unit or a transmembrane unit of a rabies virus glycoprotein (RABV-G). The molecules and antibodies typically including an antigen binding region of an antibody having six complementarity determining regions (CDRs). Also provided are antibody-conjugates (e.g., antibody-drug conjugates) and fusion proteins can include an antigen binding domain and a heterologous amino acid sequence. For example, chimeric antigen receptor (CAR) polypeptides including the provided antigen binding domains are also provided. In some forms, the CAR includes an extracellular antigen binding region, a spacer region, a transmembrane region, and intracellular signaling region. In some forms, the CAR includes a co-stimulatory domain. Nucleic acids encoding the molecules, antibodies, and fusions proteins such as CAR, and cells expressing the same are also provided. Pharmaceutical compositions including the provided compositions and methods of use thereof are also provided.

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

The present invention is directed to bi-specific diabodies that comprise two or more polypeptide chains and which possess at least one Epitope-Binding Site that is immunospecific for an epitope of PD-1 and at least one Epitope-Binding Site that is immunospecific for an epitope of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific diabody”). More preferably, the present invention is directed to bi-specific diabodies that comprise four polypeptide chains and which possess two Epitope-Binding Sites that are immunospecific for one (or two) epitope(s) of PD-1 and two Epitope-Binding Site that are immunospecific for one (or two) epitope(s) of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific, tetra-valent diabody”). The present invention also is directed to such diabodies that additionally comprise an immunoglobulin Fc Domain (“bi-specific Fc diabodies and bi-specific, tetra-valent, Fc diabodies”). The diabodies of the present invention are capable of simultaneously binding to PD-1 and to LAG-3, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such diabodies, and to methods involving the use of such diabodies in the treatment of cancer and other diseases and conditions.